share_log

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Benzinga ·  Apr 22 06:40

HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment